IncontraDonna Foundation

What IncontraDonna Foundation does

Fondazione IncontraDonna (legal entity: Fondazione IncontraDonna ETS, Codice Fiscale 97513990586) is an Italian non-profit foundation established in 2008 as IncontraDonna ONLUS and re-constituted in April 2022 under the Third Sector (ETS) framework. Its primary functional focus is breast cancer prevention, patient advocacy, and oncology health communication, with secondary extension into gynecological health, lung cancer screening advocacy, and broader women's health. The foundation serves multiple stakeholder groups: women at risk of or living with breast cancer (including the ~53,000 new diagnoses and ~40,000 women living with metastatic disease in Italy cited in its Manifesto), caregivers, the general population, youth for health literacy campaigns, and institutional partners including the Italian Ministry of Health, AGENAS, regional governments, and scientific societies.

The foundation's service portfolio comprises five core programs — Frecciarosa (15-year national train-based awareness campaign with Gruppo FS Italiane), Officina #Metastabile (PDTA co-design for metastatic breast cancer), RE-START Cancer Care (post-treatment quality of life via sports and psycho-physical activities including rowing/Vogalonga), ALT(r)AVOCE (gynecological health communication series), and the Manifesto 2025-2027 (multi-year advocacy roadmap) — plus support services including teleconsults, breast center mapping (using AGENAS PNE data), patient/caregiver support, and oncology research funding. Technical infrastructure is light: a WordPress website (incontradonna.it) available in five languages, social channels (Facebook, YouTube, LinkedIn), Zoom-based teleconsultation, and a breast unit directory. There is no proprietary software platform; no AI/ML capability is described.

The revenue model is donation- and grant-funded: individual donations (suggested €5–€500 tiers) via bank transfer and PayPal, annual membership fees (minimum €10), the Italian 5x1000 tax designation, unconditional educational grants from 15+ pharmaceutical companies (GSK, AstraZeneca, Pfizer, Roche, Novartis, MSD, etc.), and event proceeds (e.g., theatrical collaborations). Governance is by a Board of Directors (Consiglio di Amministrazione) with Founder Adriana Bonifacino, Vice President Gianfranco Battisti, General Director Sonia Carisi, and Scientific Director Prof. Paolo Marchetti coordinating a 30+ member Technical-Scientific Committee. The foundation maintains Regional Committees in 9 Italian regions and participates in Regional Oncology Networks (ROR).

Name

IncontraDonna Foundation

Legal name

Fondazione IncontraDonna

Website

https://incontradonna.it

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Short description

Fondazione IncontraDonna is an Italian non-profit foundation (ETS), founded in 2008, focused on breast cancer prevention, patient advocacy, and oncology awareness. It serves patients, caregivers, and the general Italian population through awareness campaigns (Frecciarosa), PDTA co-design (Officina #Metastabile), and institutional policy advocacy.

Ownership category

akta.pro rank

Product category

Patient Advocacy & Cancer Prevention Services

NAICS

Other Individual and Family Services (624190), Social Advocacy Organizations (81331)

SIC

Services-Social Services (8300), Services-Health Services (8000)

akta.pro primary industry

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA)

akta.pro secondary industry

Community Health, Prevention & Health Education (BPAGACAC)

Keywords

• Cancer prevention
• Patient advocacy
• Breast cancer awareness
• Oncology research support
• Health education campaigns

Headquarters

HQ city

Rome

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Marketing or Sales, Operations, Others, Technology or R&D

Revenue model

1. Donazioni da privati (Donations from private individuals): The foundation accepts one-time and recurring donations from individuals via bank transfer (Unicredit Banca di Roma, IBAN: IT93D0200805198000400072751) and PayPal ([email protected]). Online donation buttons on the website offer preset amounts of €5, €10, €20, €200, €500 plus custom amounts.
2. Quote associative (Membership fees): Individuals can become participating members of the foundation. As of January 2025, the minimum annual membership fee is €10.00, payable via bank transfer to the foundation's Unicredit account.
3. 5×1000 tax designation: Italian taxpayers can designate 5 per mille of their income tax to Fondazione IncontraDonna. The foundation's tax code (Codice Fiscale) is 97513990586. This represents a significant public funding stream.
4. Contributi e donazioni aziendali (Corporate contributions and donations): Companies can support the foundation through strategic partnerships, sponsorships, and donations. Corporate supporters include pharmaceutical companies such as GSK, Daiichi-Sankyo/AstraZeneca, Guardant Health, Menarini/Stemline, Pfizer, Amgen, Gilead, Lilly, MSD, Novartis, Roche, Takeda, Viatris, and others. These contributions are described as 'contributi non condizionanti' (unconditional contributions).
5. Proventi da eventi (Event proceeds): The foundation organizes events such as theatrical performances (e.g., 'Un altro Passo' in collaboration with Maison Gattinoni), with ticket proceeds donated to the foundation. The event held on May 25, 2026 at Spazio Rossellini in Rome generated proceeds for the foundation.

Pricing tiers

Distribution channels6 records

Marketing channels8 records

Core offering

Fondazione IncontraDonna is an Italian non-profit foundation (ETS) that delivers cancer prevention awareness, patient advocacy, and support services primarily focused on breast cancer and oncology. Its core offerings include national awareness campaigns (Frecciarosa, ALT(r)AVOCE), patient support programs (RE-START Cancer Care, teleconsults), research initiatives (Officina #Metastabile), and multi-year advocacy roadmaps (Manifesto 2025-2027).

Product overview

Fondazione IncontraDonna is a non-profit foundation (ETS) operating since 2008 focused on oncology prevention and patient advocacy. The organization offers a portfolio of awareness campaigns (Frecciarosa, ALT(r)AVOCE), patient support programs (RE-START Cancer Care, teleconsults), research initiatives (Officina #Metastabile), and advocacy activities (Manifesto 2025-2027). Core services include breast center mapping, support for patients and caregivers, oncology research funding, and community awareness campaigns, all centered on oncology and specifically breast cancer prevention and care.

Differentiator

Problem solved

Functional benefit

Products and services

• Frecciarosa National communication and awareness campaign dedicated to cancer health, prevention of tumors, and promotion of correct lifestyles. A traveling initiative conducted aboard Frecciarosa trains in collaboration with Gruppo FS Italiane, reaching millions of travelers annually across Italy.
• Officina #Metastabile Project designed for the co-design and implementation on the territory of the PDTA (Diagnostic-Therapeutic Assistance Path) dedicated to metastatic breast cancer. Involves collaboration between patients, caregivers, clinicians, and institutions.
• RE-START Cancer Care Program offering oncological patients and caregivers concrete responses to needs related to Quality of Life (HRQoL - Health Related Quality of Life). Includes sporting activities (rowing/Vogalonga), psycho-physical activities, and sharing moments to help face and overcome an oncological journey.
• ALT(r)AVOCE Project that explores complex health topics with simple, direct, and empathetic language, particularly focused on gynecological health awareness. Includes a video series (Dialoghi #Metastabili) on YouTube.
• Manifesto 2025-2027 Multi-year advocacy plan formalizing renewed commitment to Patient Advocacy with objectives focused on prevention, health literacy, screening importance, and chronic disease management over the 2025-2027 period. Signed by Senator Francesco Zaffini and 11+ patient associations.
• Patient Advocacy Activities aimed at promoting and protecting the rights of oncological patients, including participation in institutional technical tables, surveys, and collaborations with healthcare institutions and scientific societies.
• Support for Patients and Caregivers Comprehensive support services for oncological patients and their caregivers including help lines, recreational activities for wellbeing, and welfare programs.
• Teleconsults Teleconsultation service connecting patients with medical professionals, facilitating access to healthcare advice and support via Zoom-based platform.
• Breast Center Mapping Online directory of certified breast centers in Italy that meet minimum criteria for high-volume, specialized care (at least 135+ surgeries per year) in line with national and European recommendations.
• Community Awareness Communication campaigns and public events aimed at raising awareness about cancer prevention, healthy lifestyles, and the importance of early diagnosis among the Italian population.
• Oncology Research Support Funding and support for oncology research projects, including precision medicine initiatives and research on metastatic breast cancer.

Quantifiable outcome

• The FrecciaRosa campaign has been bringing oncological prevention on trains for 15 years, reaching millions of travelers annually across Italy
• +3 more outcomes

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Partnerships

28 partnerships are on record, tiered minor and core.

• Daiichi-Sankyo – AstraZenecaminorGTM or Marketing Partner · 13 October 2026Daiichi-Sankyo and AstraZeneca provided unconditional grants supporting the Officina #Metastabile 3rd edition project and the Vogalonga rowing event under RE-START Cancer Care. Logos displayed on the foundation's supporters page and event materials.
• GSKminorGTM or Marketing Partner · 13 July 2026GSK provided an unconditional educational grant (contributo non condizionante) supporting the ALT(r)AVOCE project and Herpes Zoster awareness content on Facebook. Logo displayed on the foundation's supporters page.
• Guardant HealthminorGTM or Marketing Partner · 1 April 2026Guardant Health supported the Officina #Metastabile project. Logo displayed on the foundation's supporters page.
• Menarini – StemlineminorGTM or Marketing Partner · 1 June 2025Menarini/Stemline provided unconditional support to the Officina #Metastabile project. Logo displayed on the foundation's supporters page.
• Neopharmed GentiliminorGTM or Marketing PartnerNeopharmed Gentili provided unconditional educational grant supporting the RE-START Cancer Care Vogalonga rowing event.
• Fondazione RomaminorGTM or Marketing PartnerFondazione Roma thanked as a supporter of the RE-START Cancer Care Vogalonga rowing event.
• PfizerminorGTM or Marketing PartnerPfizer displayed as a supporter (sostenitore) of Fondazione IncontraDonna. Provides unconditional educational grants for awareness campaigns.
• AmgenminorGTM or Marketing PartnerAmgen listed as a supporter (sostenitore) of Fondazione IncontraDonna on the corporate partnership page.
• RocheminorGTM or Marketing PartnerRoche listed as a supporter (sostenitore) of Fondazione IncontraDonna on the corporate partnership page.
• NovartisminorGTM or Marketing PartnerNovartis listed as a supporter (sostenitore) of Fondazione IncontraDonna on the corporate partnership page.
• MSDminorGTM or Marketing PartnerMSD listed as a supporter (sostenitore) of Fondazione IncontraDonna on the corporate partnership page.
• GileadminorGTM or Marketing PartnerGilead listed as a supporter (sostenitore) of Fondazione IncontraDonna on the corporate partnership page.
• LillyminorGTM or Marketing PartnerLilly listed as a supporter (sostenitore) of Fondazione IncontraDonna on the corporate partnership page.
• TakedaminorGTM or Marketing PartnerTakeda listed as a supporter (sostenitore) of Fondazione IncontraDonna on the corporate partnership page.
• ViatrisminorGTM or Marketing PartnerViatris listed as a supporter (sostenitore) of Fondazione IncontraDonna on the corporate partnership page.
• BeOne MedicinesminorGTM or Marketing PartnerBeOne Medicines listed as a supporter (sostenitore) of Fondazione IncontraDonna on the corporate partnership page.
• Bristol Myers Squibb (BMS)minorGTM or Marketing PartnerBristol Myers Squibb listed as a supporter (sostenitore) of Fondazione IncontraDonna on the corporate partnership page.
• Gruppo FS ItalianecoreStrategic or Co-development PartnerFondazione IncontraDonna has partnered with Gruppo FS Italiane (Ferrovie dello Stato) for 15 years on the FrecciaRosa campaign, bringing cancer prevention information and awareness on board Frecciarosa trains across Italy. This is the foundation's flagship awareness delivery channel.
• AGENAS (Agenzia Nazionale per i Servizi Sanitari Regionali)coreStrategic or Co-development PartnerAGENAS collaborates with the foundation on breast unit mapping. The foundation uses AGENAS-processed PNE (Piano Nazionale Esiti) data to display certified breast units on its website. A formal convention exists between AGENAS and the foundation for collaboration.
• Ministero della Salute (Ministry of Health)coreStrategic or Co-development PartnerThe Ministry of Health provides official patronage for the FrecciaRosa campaign and other initiatives. Sergio Iavicoli, Director General of Prevention at the Ministry, participated in the Manifesto press conference. The foundation contributes to national health policy discussions.
• Maison GattinoniminorStrategic or Co-development PartnerMaison Gattinoni collaborated with the foundation on the theatrical performance 'Un altro Passo', combining fashion and science to raise oncology awareness. The event took place at Spazio Rossellini, Rome, on May 25, 2026.
• Senatore Francesco Zaffini (Presidente Commissione Sanità, Lavoro e Previdenza di Palazzo Madama)coreStrategic or Co-development PartnerSenator Zaffini, President of the Senate Health, Labor and Social Security Commission, signed the Manifesto 2025-2027 and participated in a public event, advocating for recognizing prevention as an investment rather than a cost in national health policy.
• AGENAS – Rete Italiana Screening Polmonare (RISP)minorStrategic or Co-development PartnerFondazione IncontraDonna is engaged in advocacy for lung cancer screening implementation, referencing the 18 RISP centers established with €2 million in ministerial funding per DM November 8, 2021.
• Fondazione AIOMcoreStrategic or Co-development PartnerFondazione AIOM (Associazione Italiana di Oncologia Medica) is a listed institutional collaborator. The foundation participates in Fondazione AIOM's CDA (Board of Directors) activities. Joint advocacy on AIOM guidelines and patient pathways.
• Intermedia News (Press Office)minorGTM or Marketing PartnerIntermedia News serves as the foundation's press office (ufficio stampa), handling media relations, privacy, creative, app, and web services. Contact: [email protected].
• 11+ Patient Associations signatories to Manifesto 2025-2027coreStrategic or Co-development PartnerThe Manifesto 2025-2027 was co-signed by multiple patient organizations including: Amici Obesi Onlus, Associazione Preziosa, Cittadinanzattiva Lazio, Fondazione Aiom, Antea, Fondazione Sportcity, Gemme Dormienti Onlus, Loto OdV, Oltre il nastro rosa, Vivere senza stomaco si può, WALCE APS.
• WEB-AISF (International Association of Breast Surgery)coreStrategic or Co-development PartnerListed as a collaborator on the foundation's website. WEB-AISF is an international breast surgery association providing scientific credibility and network support for breast unit standards.
• Multiple Scientific and Medical Societies (listed as collaborators)coreStrategic or Co-development PartnerThe foundation maintains collaborations with over 20 Italian scientific societies including: ANISC, ACOI, AIMN, Radioterapia Italia, AISPO, Associazione Italiana Tiroide, AITER, CIPOMO, FESIN, Fondazione FMP, SIAPEC, SIPO, SITI, SIUMB, SIPROMAZIONE SALUTE, Società Italiana di Endocrinologia, SIP, SIMEN, SIMDO, Cancerologia, SIGG, SIRM. These societies provide scientific validation and institutional credibility.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Fondazione Telethon: Major Italian nonprofit funding genetic disease research with significant public fundraising (TV marathon model) and 5x1000 presence. Comparable scale of national nonprofit health organization competing for Italian donor mindshare and tax designations.
• Susan G. Komen (Global): Global breast cancer nonprofit with the largest international footprint in breast cancer awareness, research funding, and patient advocacy. Comparable as a breast cancer-specific awareness and donor-funded organization with similar campaign-driven model.
• AIRC (Italian Foundation for Cancer Research): Italy's largest cancer-focused nonprofit, funding cancer research across all tumor types. Directly comparable as a disease-specific health nonprofit competing for the same Italian 5x1000 designations, individual donations, and corporate grants.

Direct peers

• Cittadinanzattiva: Italian civic advocacy organization promoting citizens' rights in health and public services. Comparable as a patient/citizen advocacy nonprofit with a Manifesto co-signatory (Cittadinanzattiva Lazio) and similar institutional-policy engagement model.
• Europa Donna Italia: Italian branch of the European breast cancer advocacy coalition, focused specifically on breast cancer policy and patient rights. Highly comparable mission and patient-advocacy model targeting the same primary patient population.
• WALCE APS: Italian patient association dedicated to women against lung cancer in Europe. Comparable nonprofit model with focus on a specific cancer, advocacy, and Manifesto co-signatory relationship.
• Susan G. Komen Italia: Italian affiliate of the global breast cancer nonprofit, running awareness campaigns (Race for the Cure) and funding research. Directly comparable as a breast cancer-specific advocacy organization with event-driven awareness and donor-funded model.
• Fondazione AIOM: Foundation of the Italian Association of Medical Oncology, focused on oncology research and patient advocacy. Already a partner and co-Manifesto signatory; directly comparable as a clinical-society-affiliated cancer advocacy foundation.
• AIMaC (Associazione Italiana Malati di Cancro): Italian association supporting cancer patients and families with information, helplines, and advocacy. Directly comparable as a patient-support and information-services nonprofit in the Italian oncology ecosystem.
• LILT (Italian League for the Fight Against Cancer): National nonprofit focused on cancer prevention, early diagnosis, and patient support across Italy. Closely aligned mission of cancer prevention awareness, screening advocacy, and patient navigation with regional presence similar to IncontraDonna's Comitati Regionali.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCOMgCUH9ye9S3Wm1YQxYofQ
• Facebookfacebook.com/FondazioneIncontraDonna
• LinkedInlinkedin.com/company/incontradonna

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IncontraDonna Foundation